This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

MiMedx Group Inc (MDXG)

NASDAQ: Health Care

$7.16 -0.22 | -2.98%
05/03/16 - 3:59:00 PM ET
  • Prev Close: 7.38
  • Day's Open: 7.36
  • Volume: 1.42M
  • Avg Vol: 900.80K
  • Shares Outstanding: 107.81M
  • Mkt Cap: 811.81M
  • Div: --
  • Div Yield: --
  • P/E: 44.29
  • EPS: 0.30
MDXG Day's Range
$7.0650
$7.4550
MDXG 52 Week Range
$6.71
$13.20
Trade Now:
MDXG Business Summary
MiMedx Group, Inc. develops, processes, and markets regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues, and human skin and bone. Its biomaterial platform technologies are AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix.View MDXG key stats
MiMedx Group Inc - MDXG - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates MiMedx Group Inc as a Hold with a ratings score of C+.
Report Snippet: We rate MIMEDX GROUP INC (MDXG) a HOLD. The primary factors that have impacted our rating are mixed – some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its robust revenue growth, reasonable valuation levels and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, weak operating cash flow and a generally disappointing performance in the stock itself.
Rating: 3.00 out of 5, 'C+' Hold.
You can view the full analysis from the report here:
MDXG Rating Report
MDXG Performance as of Prev. Close
YTD
-21.24%
3-Mo
-5.63%
1-Yr
-20.04%
3-Yr
9.01%
MDXG EPS Performance
1-Yr Ago
0.30
2-Yrs Ago
0.10
3-Yrs Ago
-0.00
MDXG News

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

MDXG MiMedx Group Inc

Chart of MDXG

Analysts Ratings for MDXG

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 5 6 6 6
Moderate Buy 0 0 0 0
Hold 1 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET MDXG ANALYST REPORT

MDXG Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs